Search
Adipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
Corticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. … (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Categories: Hormones, Hormone Substitutes, and Hormone AntagonistsCY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalLaquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.
Chloroxine
go.drugbank.com/drugs/DB01243ApprovedWithdrawnChloroxine is a synthetic antibacterial compound. Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.
Metrizamide
go.drugbank.com/drugs/DB01578ExperimentalIt is also used as a resorbable, non-ionic contrast medium. … Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity.
Categories: Compounds used in a research, industrial, or household settingMidomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalAn N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Polydatin
go.drugbank.com/drugs/DB11263ApprovedIt is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229]. … and many daily diets [A27226].
V590
go.drugbank.com/drugs/DB16437ExperimentalBy teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow protocol[L30583].